- The Washington Times - Wednesday, March 18, 2009

WASHINGTON (AP) - A panel of cardiology experts recommends that an experimental drug from Sanofi-Aventis be approved to treat irregular heart rhythms linked to stroke.

The Food and Drug Administration’s cardiology drug panel voted 10 to 3 in favor of approving the drug Multaq for that use. The drug is designed to treat atrial fibrillation, a condition that interferes with the beating of the heart’s upper chambers.

The FDA is not required to follow the group’s advice, though it usually does. The agency is scheduled to make a final decision on the drug by April 30.

If approved, Multaq would be the first new treatment for atrial fibrillation in more than 25 years.

Copyright © 2018 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide